MENU
Go to the list of all blogs
Niko Sharks's Avatar
published in Blogs
Dec 10, 2023

Installation Industry Stocks($NBIX, $ACAD, $ALKS, $MDXG, $CYCCP...) Surge with an Average 19.6% Monthly Gain📈

The installation industry, particularly in the residential segment, has seen a remarkable surge in stock performance over the past month. Companies operating in this sector, such as Masco Corp. (MAS), Installed Building Products Inc. (FIX), and nVent Electric plc. (NVT), have all contributed to this impressive performance.

🌐Tickers in Industry - $NBIX, $ACAD, $ALKS, $MDXG, $CYCCP, $VCEL, $VTGN, $MRNA 

Choppy Market Trader, Popular Stocks: Market Neutral Strategy (TA&FA) - Annualized Return + 107%

Theme and Group of Tickers Inside the Theme

The theme in focus here is the installation industry, with a specific emphasis on companies engaged in manufacturing home products and items related to home improvement. The notable tickers within this theme include:

  1. Masco Corp. (MAS): Specializes in building and home improvement products.
  2. Installed Building Products Inc. (FIX): Primarily involved in insulation installer operations.
  3. nVent Electric plc. (NVT): Specializes in electrical connections.

Market Cap

The average market capitalization for companies within the installation theme is approximately $5.6 billion. However, there is significant variation within this group, with market caps ranging from $52.3 million to $13.4 billion. Masco Corp. (MAS) holds the highest valuation at $13.4 billion, while the lowest valued company is KEQU at $52.3 million.

High and Low Price Notable News

In the past month, stocks within the installation theme have experienced substantial price movements. On average, these stocks have seen a remarkable monthly price growth of 19.6%. The average weekly price growth was 6.44%, and the average quarterly price growth was 25.83%.

Notable price movements in this theme include Masco Corp. (MAS) witnessing a significant weekly decline of -5.16% and, in contrast, a weekly gain of +5.43%. nVent Electric (NVT) also saw a notable weekly gain of +5.79%, reflecting the volatility and potential for substantial returns in this sector.

Volume

The trading volumes for stocks in the installation theme have exhibited some interesting trends. On average, there was a weekly volume decrease of -4.76% in the past month, while the monthly and quarterly volume trends showed even more significant declines of -34.01% and -16.5%, respectively.

It's worth noting that nVent Electric's stock witnessed a remarkable daily volume growth of 99% of the 65-Day Volume Moving Average on August 1, 2023. Similarly, Griffon stock experienced a one-day volume surge, reaching a growth of 296% of the 65-Day Volume Moving Average on June 17, 2023.

Fundamental Analysis Ratings

While specific fundamental analysis ratings are not provided in the information given, it's clear that the installation industry, particularly in the residential segment, is exhibiting strong performance. The impressive monthly price growth of 19.6% underscores the sector's potential for investors seeking growth opportunities.

The installation industry, encompassing companies involved in home improvement and related products, has shown outstanding stock performance over the past month. Investors should take note of the opportunities presented by stocks like Masco Corp. (MAS), Installed Building Products Inc. (FIX), and nVent Electric plc. (NVT) in this thriving sector.

NBIX : On November 24, 2023, NBIX exhibited a noteworthy shift in its trajectory as it crossed above its 50-day Moving Average. Historically, such occurrences have often translated into positive momentum, with 32 out of 39 comparable instances resulting in subsequent price increases over the following month. With an 82% probability, the odds appear favorable for NBIX to sustain its upward trajectory. Investors may find this development an encouraging sign for potential gains in the near future.

ACAD : ACAD Pharmaceuticals recently exhibited a notable shift in its stock trajectory, breaching its 50-day Moving Average on December 5, 2023. This movement signifies a potential reversal from its previous upward momentum to a bearish trend. Historical analysis reveals that in 35 out of 45 comparable scenarios, ACAD's stock experienced further decline in the subsequent month. This pattern suggests a 78% probability of the stock continuing its downward trend. Investors and market analysts are closely monitoring this development, considering its implications for future investment strategies and market positioning related to ACAD.

ALKS : ALKS Pharmaceuticals exhibited a significant shift in market sentiment as its Momentum Indicator ascended above the zero mark on November 16, 2023. This transition is widely interpreted as a precursor to a new upward trend in the stock's performance. Investors and traders are advised to consider strategies like purchasing shares or opting for call options in anticipation of potential gains. Tickeron's A.I.dvisor analyzed 95 comparable events where the indicator turned positive. In 76 of these instances, ALKS's stock price increased in the subsequent period, indicating an 80% likelihood of a continued upward movement. This trend presents a promising opportunity for market participants focusing on ALKS.

 

Related Ticker: NBIX, ACAD, ALKS, MDXG, CYCCP, VCEL, VTGN, MRNA

NBIX's RSI Indicator ascends from oversold territory

The RSI Oscillator for NBIX moved out of oversold territory on April 14, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In of the 31 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 21, 2025. You may want to consider a long position or call options on NBIX as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NBIX just turned positive on April 16, 2025. Looking at past instances where NBIX's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NBIX advanced for three days, in of 298 cases, the price rose further within the following month. The odds of a continued upward trend are .

NBIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for NBIX entered a downward trend on April 07, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.297) is normal, around the industry mean (61.171). P/E Ratio (57.202) is within average values for comparable stocks, (90.174). Projected Growth (PEG Ratio) (0.464) is also within normal values, averaging (2.987). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (7.564) is also within normal values, averaging (20.123).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NBIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NBIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), Tilray Brands (NASDAQ:TLRY), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 3.65B. The market cap for tickers in the group ranges from 246 to 77.48B. ZTS holds the highest valuation in this group at 77.48B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 3%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was -11%. SXTC experienced the highest price growth at 71%, while MGWFF experienced the biggest fall at -54%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 28%. For the same stocks of the Industry, the average monthly volume growth was 64% and the average quarterly volume growth was 102%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 67
Price Growth Rating: 66
SMR Rating: 82
Profit Risk Rating: 89
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a product based biopharmaceutical company

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12780 El Camino Real
Phone
+1 858 617-7600
Employees
1400
Web
https://www.neurocrine.com